Centene
NYSE: CNC
$63.41 ▼ -0.33  (-0.52%)
At close: Jul 24, 2026 · 4:03 PM UTC
Financial Ratios
Market Cap31.35 Bn
P/E-4.86
P/S0.17
Div. Yield0.00
ROIC (Qtr)-0.49
Total Debt (Qtr)16.37 Bn
Revenue Growth (1y) (Qtr)-4.21
Add ratio to table…

About

Centene is a managed care company that focuses on providing health care services to underserved populations across the United States. The company delivers Medicaid Medicare and commercial health insurance products along with ancillary services such as specialty pharmacy vision dental and behavioral health. Its mission is to improve the health of the communities it serves one person at a time through local partnerships and data driven approaches. Centene generates revenue…

Read more ↓
Sector: Healthcare Industry: Healthcare Plans CIK: 0001071739

Investment Thesis

▲ Bull case
  • Centene demonstrates significant operational resilience and strategic positioning through its diversified portfolio across Medicaid, Medicare, and Marketplace segments, with early 2026 results showing tangible progress in margin recovery despite near-term headwinds. The company reported Q1 FY26 adjusted diluted EPS of $3.37, significantly exceeding analyst expectations of $2.13 and reflecting effective cost management, as evidenced by a health benefits ratio (HBR) of 87.3%—well below the analyst consensus of 89.42%. This performance was driven by disciplined SG&A management, moderate flu season costs, and proactive interventions in high-cost areas like specialty pharmacy, where Centene leveraged the Inflation Reduction Act to secure favorable risk corridor protections in its PDP business. The company's ability to generate $4.4 billion in operating cash flow during Q1 FY26—nearly triple the prior year—underscores strong working capital efficiency, particularly from improved timing on pharmacy rebate remittances, providing substantial financial flexibility to fund strategic initiatives without relying on external capital. Furthermore, Centene's decision to increase its full-year FY26 adjusted diluted EPS guidance to greater than $3.40 (from a prior expectation of more than $3.00) signals management's confidence in sustaining margin improvement, supported by the rollout of Medicare's GLP-1 cost negotiation program starting July 1, 2026, which directly addresses a key cost driver in its Medicare Advantage segment. The company's scale—serving over 26 million at-risk members—creates a durable competitive advantage in negotiating with providers and state partners, while its unregulated cash position of $437 million and a $4 billion undrawn revolving credit facility (with only 39% debt-to-capital usage) offers ample liquidity to navigate near-term volatility. Most critically, Centene's entrenched role in government-sponsored programs—particularly Medicaid, where 88% of its membership undergoes rate redetermination between July 2025 and January 2026—provides a clear pathway to margin expansion, as the company has historically secured outsized rate increases by leveraging real-time data and state partnerships, a capability it is actively reactivating to counter recent medical cost trends in behavioral health and home health services.
  • Centene's Marketplace business, while pressured in 2025 by a $2.4 billion pretax earnings headwind from risk adjustment morbidity shifts, is positioned for a meaningful turnaround in 2026 through aggressive repricing actions informed by granular, state-level data analytics. The company has already filed 2026 pricing in 17 states and expects to submit adjusted filings in up to 12 additional states within weeks, targeting 100% repricing of its 29-state Marketplace book to account for both observed 2025 morbidity shifts (driven by healthy member attrition, higher-morbidity new entrants, and aggressive provider coding) and anticipated 2026 dynamics under renewed program integrity measures. Unlike peers who may rely on broad market assumptions, Centene's unique 29-state footprint allows it to correlate local market disruptions—such as the 16-17% year-over-year morbidity shifts in states with low-cost Silver plan changes—and bake these insights into prospective pricing, reducing the risk of further underpricing. The company's proactive engagement with federal administrators to shape program integrity mechanics for 2026 open enrollment ensures that pricing assumptions align with actual enrollment behavior, mitigating the risk of repeat surprises. Moreover, Centene frames the 2025 Marketplace attrition as a "pull forward" of expected 2026 market contraction, meaning it has already absorbed some of the membership decline that peers are still forecasting for 2026, thereby lowering its forward-looking risk. With eAPTC expiration already priced into initial 2026 filings and the company actively advocating for transparency in risk adjustment data dissemination (e.g., earlier demographic data sharing via CMS or Wakely), Centene is building structural advantages that could accelerate profitability restoration beyond its 2026 target, especially if Wakely's September and December 2026 data reveals less severe morbidity shifts than currently modeled, thereby reducing the need for the $200 million back-half utilization reserve built into its 2025 forecast.
  • Centene's Medicaid segment, despite a Q2 FY25 HBR of 94.9% driven by acute pressures in behavioral health (particularly ABA in Florida), home health, and high-cost drugs, exhibits a clear and executable path to sustainable margin improvement through a combination of rate advocacy, clinical intervention scaling, and state partnership deepening—factors underappreciated by the market's near-term focus on volatility. The company has already secured material rate updates effective July and September 2025 that exceeded prior expectations (now projecting a 2025 composite rate adjustment of 5% versus the earlier 4%+ forecast), with 40% of its Medicaid membership set to receive January 2026 rate updates incorporating current trend data, directly addressing the root cause of margin compression. Crucially, Centene is moving beyond reactive rate chasing by embedding real-time data into state deliberations—advocating for mid-year rate cycles in states that have adopted them—and leveraging its 30-state footprint to propagate best practices, such as Florida's shift away from a single PBM model, which will allow Centene to exert greater pharmacy cost control starting October 2025. The company's enterprise-wide task forces for behavioral health and ABA are already yielding progress in targeted states like Florida (where the continuity of care provision lifted June 1, 2025) and New York (where state collaboration on fraud, waste, and abuse is improving), demonstrating that its focused levers—network optimization, clinical guideline alignment, and utilization management—can bend trend without relying solely on rate increases. Furthermore, Centene's long-term conviction in Medicaid's "staying power" is reinforced by the One Big Beautiful Bill Act (OB3), which preserved core program financing while rejecting far more disruptive proposals like per capita caps or block grants, signaling bipartisan durability; this, combined with Centene's investments in digital enrollment and work requirement verification systems (enabled by OB3's TCPA modernization), positions it to minimize procedural disenrollment and maintain coverage for eligible members, thereby stabilizing its risk pool and supporting margin recovery over the next 12–18 months as rate corrections take full effect.
▼ Bear case
  • Centene's Marketplace segment faces structural and persistent headwinds that are likely to extend beyond 2026, as the company's repricing strategy may fail to fully capture the evolving risk pool dynamics driven by irreversible shifts in member behavior and federal policy, leaving it vulnerable to chronic underperformance despite aggressive rate actions. While Centene claims it will reprice 100% of its Marketplace book for 2026 to address the $2.4 billion pretax earnings headwind from 2025 morbidity shifts, its approach remains reactive—relying on historical Wakely data to forecast future risk—rather than anticipating how federal program integrity measures (e.g., mandatory eligibility verifications, social security checks) will continuously deter healthy enrollment and incentivize provider-side coding aggression year over year. The company's own analysis acknowledges that the 2025 morbidity shift was partly a "pull forward" of expected 2026 attrition, yet it has not adjusted its long-term membership assumptions downward sufficiently; with current Marketplace membership at 5.9 million and a projected year-end 2025 figure of 5.4 million, further attrition in 2026 open enrollment could easily push membership below 5.0 million if the 15–50% contraction range cited by management proves accurate, directly undermining the economies of scale needed to sustain profitability in a low-margin, volume-driven business. More critically, Centene's pricing strategy assumes it can offset morbidity shifts through rate increases, but in a federal exchange environment where premium tax credits (eAPTCs) are expiring and price sensitivity is acute, any significant rate hike risks triggering additional disenrollment among low-utilizing, price-sensitive members—thereby worsening the risk pool in a vicious cycle. The company's hope to leverage its scale for greater transparency in risk adjustment data (e.g., earlier demographic data sharing) is unlikely to materialize quickly enough to impact 2026 pricing, as federal data sharing protocols are notoriously slow and subject to political constraints, leaving Centene exposed to repeated pricing misses if morbidity continues to shift faster than its refiling cycle can adapt.
  • Centene's Medicaid margin recovery is significantly overstated in its guidance, as the company's reliance on rate increases to counteract rising medical costs ignores the structural limitations of state budget processes and the growing risk of eligibility-driven disenrollment from OB3 provisions, which could destabilize its risk pool and elevate long-term costs despite near-term rate relief. Although Centene projects a 2025 composite Medicaid rate adjustment of 5% and cites improved 7/1 and 9/1 rate outcomes, it remains vulnerable to delays or inadequacies in the 10/1 state updates—particularly in high-impact markets like Florida—where historical rate insufficiency and state-driven program changes (e.g., in New York's HCBS program) have repeatedly undermined cost containment efforts. The company's assumption that Medicaid HBR will improve to 93.5% in the second half of 2025 hinges on optimistic clinical intervention success and fraud reduction, yet it admits it is not baking in potential retroactive premium adjustments for inadequately rated populations like Florida's Children's Medical Services (where it is the sole source carrier) or New York's risk correction needs—both of which could add hundreds of millions in unmodeled costs if pursued. More alarmingly, Centene's confidence in Medicaid's "staying power" overlooks how OB3's work requirements and 6-month verification mandates—though affecting a small share of expansion adults—could trigger widespread procedural disenrollment due to documentation burdens, a phenomenon observed during the Medicaid redeterminations era where eligible members lost coverage for failing to submit paperwork. While Centene cites its history in states with work requirements as a strength, scaling digital enrollment and verification systems across 30 states requires significant investment and coordination, and any lag in implementation could exacerbate disenrollment among vulnerable populations, worsening the risk pool by removing healthier, lower-cost members and leaving behind a sicker, more expensive base—directly counteracting margin improvement efforts even if rates rise. Furthermore, the company's reliance on beating trend through clinical interventions (e.g., in behavioral health and home health) is unproven at scale, as state partners remain fragmented in adopting evidence-based guidelines, and Centene's influence is limited to advocacy, not control, leaving it exposed to persistent cost pressures that could keep HBR elevated above 93% through 2026 and beyond.
  • Centene's Medicare Advantage path to breakeven by 2027 and profitability thereafter is increasingly uncertain due to intensifying competitive pressure, unsustainable reliance on Part D tailwinds, and the limited durability of its current operational improvements, which may not withstand future CMS policy shifts or rising acuity in its aging member base. While the company credits its Medicare segment for delivering approximately $700 million in pretax favorability versus prior forecasts—driven by PDP performance and better-than-expected MA results—it overemphasizes the stability of its PDP business, which benefits temporarily from the Inflation Reduction Act's risk corridor protections (90% CMS, 10% payer) but remains exposed to volatile specialty pharmacy trends in its non-low-income cohort, with no guarantee the demo will continue beyond its current term. The company's Medicare Advantage progress, though framed as "on track" for a 2027 breakeven, relies heavily on current-year pricing discipline and footprint optimization, yet offers no concrete plan to counteract looming CMS cuts to benchmark payments or quality bonus payments, which could erode margins as early as 2026 if STARS improvement stagnates—especially given Centene's admission that challenging cut points may make its 85% target difficult to hit. Furthermore, the company's assumption that it can leverage SG&A and value-based care initiatives to drive MA profitability ignores the reality that its MA membership is flat year-over-year (7.8 million in Q2 FY25) and increasingly concentrated in higher-acuity, dual-eligible populations—a segment that requires more intensive care management and yields lower margins than traditional MA members. Without a clear strategy to attract or retain lower-risk, younger seniors, Centene's MA business risks becoming a high-cost, low-margin liability, particularly as CMS pushes further toward value-based care and direct contracting models that favor integrated players with stronger clinical infrastructure—areas where Centene has historically lagged behind peers like UnitedHealthcare in care coordination and outcomes improvement. The company's hope to "harvest synergies" across its platform is vague and unquantified, and its plan to "pressure-test markets for future conditions" lacks specificity on how it will address the fundamental mismatch between its operational model and the evolving demands of Medicare Advantage in a post-IBB environment where efficiency and integrity are paramount.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Healthcare Plans
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 UNH Unitedhealth Group Inc 384.70 Bn30.020.9077.92 Bn
2 CVS CVS HEALTH Corp 136.05 Bn46.861.8463.11 Bn
3 ELV Elevance Health, Inc. 82.25 Bn16.640.4531.04 Bn
4 CI Cigna Group 75.16 Bn11.500.7530.90 Bn
5 HUM Humana Inc 47.47 Bn38.910.4613.99 Bn
6 CNC Centene Corp 31.35 Bn-4.860.1716.37 Bn
7 MOH Molina Healthcare, Inc. 10.44 Bn54.340.243.77 Bn
8 OSCR Oscar Health, Inc. 8.62 Bn-218.951.150.43 Bn